Audit: QRS - KPV for Health & Longevity
Audit conducted on 05/08/2026 12:06 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 82 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every dose, threshold and range traced to the ER: 200–500 µg SC and 500 µg–1 mg oral (ER Therapeutic Protocol), 0.5–1% topical, 4–8 week blocks, CD4 < 200 cells/µL, neutrophils 1.5 × 10⁹/L, all seven biomarker targets, and the cadence text. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges carried through: “Figures from clinician-educator networks and compounding pharmacies, not trials”, “From practitioner protocols; consistent with animal colitis models but not evidence. No human data define this”, “no published toxicology”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain absolute framing; benefit tiers retain ER grades; no Medium/Low benefit is promoted, and benefits_high is suppressed rather than populated. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER’s “Populations who should avoid KPV entirely” list plus “Competitive sport”, which the ER itself labels “(absolute contraindication)”. No Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers or investigator names appear anywhere in the QRS. All drug and peptide names (cephalexin, valacyclovir, tacrolimus, infliximab, BPC-157, TB-500, rapamycin, etc.) appear in the ER Key Interactions section for the same fact. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Only attribution is “clinician-educator networks and compounding pharmacies”, taken from the ER Therapeutic Protocol bullet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sober, provenance-flagging register; phrasing such as “continuing without a measured change is continuing on hope” is lifted from ER Practical Considerations. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents thresholds, tiers and measurable endpoints that let a reader decide and self-assess, without either promotion or admonition. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells describe what is done in practice and name the provenance rather than instructing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives; the sheet reports practice patterns, gates and markers. Footer disclaimer is unchanged from the template. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should” or “must” in QRS content. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the QRS content. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained (PepT1, hs-CRP, eGFR, ALT) are all necessary to the Monitoring and Interactions gates and are used exactly as in the ER; no gratuitous jargon added. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every card is reduced to headings, values and short fragments; no ER prose is carried over verbatim at paragraph length. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address anywhere. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a self-directed user weighing an uncharacterised compound: quality-of-supply gate, baseline testing, defined assessment window. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Two-occasion baseline testing, a seven-marker panel and daily symptom scoring all assume high willingness to invest effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Optimal functional ranges rather than conventional laboratory cut-offs are used throughout the Monitoring table. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance and the Risk card foreground the two decision-relevant facts for this audience — no human trial in forty years, and supply outside pharmaceutical quality standards. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear in the QRS; the ER’s quoted academy name was not carried over. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “subcutaneously”, “enteric-coated”, “peptidase degradation”, “hypersensitivity”, “adverse” register maintained; no consumer-grade substitutions. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Line-by-line comparison against [qrs_template] shows all fixed headings, gate headings, tier labels and table headers byte-identical. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variables present; the indexed patterns are expanded as intended — marker_#* to marker_1..7* and qualitative_item_# to qualitative_item_1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website=”evidence_review”, website=”audit”, website=”full_review”) are untouched, as are all CSS rules and the footer disclaimer. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No section of the source ER is empty; every ER section mapped onto the QRS carries content. The empty benefits High tier is governed by item 12.5, which requires suppression rather than empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1..3_label are the ER Therapeutic Protocol bold labels verbatim (“Standard practice protocol”, “Best time of day”, “Single versus split dosing”); the six qualitative_item bold labels and all seven marker names are verbatim from the ER. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | The three time labels are lifted from the ER’s own wording in Practical Considerations (“gut-related changes”, “skin-related changes”, “assessment window”), not invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji anywhere in the QRS; the ER’s tier emojis and the “⚠️ Conflicted” markers on Direct Antimicrobial Activity and Impairment of Host Defence were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the template’s per-section budget: benefit and risk tiers reduced to semicolon-separated headings, gate items to single fragments, Monitoring “Why” cells to short clauses. No section carries ER prose at paragraph length. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: single comment opening immediately after <!doctype html> on line 1, before the template comment and <html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3 and closing --- on line 13; the descriptive text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed entirely in an HTML comment; no metadata value is repeated in head or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: "00:05" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: kpv_2026-0805-0820_Opus_ER.md, which matches the source ER on disk. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0805-1145, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version only, no context-window or other qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: kpv_2026-0805-0820_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user: evipedia-1 and git_issue: 4795; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “KPV for Health & Longevity - Quick Reference Sheet”; canonical_topic matches the ER frontmatter and the ampersand is entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “KPV for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0805-1145 → “08/05/2026”. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”, identical to the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only title and the template subline; the ER’s “Also known as” list (Lys-Pro-Val, α-MSH 11-13, etc.) was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences condensing the ER Conclusion’s four movements: what KPV is, where the preclinical case is strongest, the absence of human testing, and supply quality. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four statements maps to a distinct ER Conclusion passage; no synthesis beyond it. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “three-amino-acid fragment of a natural human hormone”, “switch off inflammation”, “darkening skin” — the ER’s own plain-language register; no acronym other than the intervention name itself. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial, author or year is named. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result of any kind; “more than forty years” is a duration, not an effect size. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items trace to that ER section — seven from “Populations who should avoid KPV entirely” plus the competitive-sport bullet marked “(absolute contraindication)”. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Complete: pregnancy/lactation, malignancy, transplant/immunodeficiency, active untreated infection, low counts, under-18s, untested product, competitive sport. None omitted, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every trailing ER clause is stripped, e.g. “— no tumour-surveillance data, and the mechanism gives theoretical grounds for concern” and “— antipyretic and anti-inflammatory activity can mask progression”. No dash-trailing content remains in any item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Preserved: “in remission for less than 5 years”, “(CD4 below 200 cells/µL)”, “below 1.5 × 10⁹/L”/”below 1.0 × 10⁹/L”, “under 18”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Eight stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map one-to-one onto the ER’s interaction bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ER’s ten interaction bullets are carried; “Competitive sport” is correctly excluded here because it is placed in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “Clinical consequence”/”Mitigation” prose is stripped from every item; no dash-trailing clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every item retains its named-drug list, trimmed to representative members (e.g. β-lactams “(cephalexin, amoxicillin)”, biologics “(infliximab, adalimumab, ustekinumab, tofacitinib)”); none is dropped entirely. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Nine caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol bullets; the ER’s provenance caveat about commercial actors is retained in condensed form. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose and route, timing relative to food, and single-versus-split dosing — the only three bullets in the ER Protocol section that specify an executable parameter. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields populated; each sub adds the ER’s route variants, competing considerations and provenance rather than filler. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Gut-related change (1–2 weeks), skin-related change (3–4 weeks) and assessment window (4–8 weeks) — the three aspects given in the ER “Time to effect” bullet. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Gut first (the ER’s only Medium-tier benefit), skin second (Low tier), overall assessment window third. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields populated; each sub carries the ER’s evidential caveat (“From practitioner protocols”, “No human data define this”). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Each entry corresponds to an ER Expected Benefits heading at the matching tier. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and correctly assigned. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to bare headings: e.g. all six Low-tier benefits as a semicolon list; no Magnitude text, nanomolar concentrations or 3.8-fold accumulation figures carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any benefits entry. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records no High-tier benefit; benefits_high carries style="display: none" and an emptied item rather than empty-state text. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten entries correspond to ER risk headings at the matching tier. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to headings; the ER’s “Magnitude” lines (zero trials in 40 years, 0 of 7 peptides approved) and the “⚠️ Conflicted” marker are not carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any risks entry; the ER’s glosses such as “(redness)” and “(raised bumps)” are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers carry items in the ER, so no span needs suppressing. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both derive from ER “Monitoring Protocol & Defining Success”. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarkers present with targets verbatim: hs-CRP, fecal calprotectin, IL-6, complete blood count with differential, comprehensive metabolic panel, ferritin, fasting insulin. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Carries baseline on two occasions a week apart, full panel at 8 weeks and end of first off-period, then every 3–6 months, with the 4-week blood count and liver panel trigger. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six entries derive from the ER’s qualitative marker bullets in that section. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six present: gastrointestinal symptom burden, joint stiffness and morning function, skin appearance and reactivity, energy and post-exertional recovery, cognitive clarity and mood, sleep quality and continuity. |
Issues 05/08/2026 12:06
Pass rate 100.00%. No issues found.
Issues 05/08/2026 11:52
- 2.5 — Imperative dosing instruction: [action_1_sub] (line 457) states “Run in blocks of 4–8 weeks.” as an imperative, which advises rather than presents; the ER phrases it descriptively as part of the regimen description (ER line 387).
- 4.5 — Sheet overflows one A4 page: The rendered sheet runs to roughly two A4 pages (~6,900 characters of body text against a ~774pt budget), driven mainly by the nine multi-line [caution_items] (lines 603–637), seven two-line Monitoring “why” cells (lines 686–789), six multi-line qualitative items (lines 807–845), four-sentence protocol subs (lines 454–539) and the four-line [monitoring_cadence] (lines 794–799).
Fixes 05/08/2026 11:52
- 2.5 — Imperative dosing instruction removed: [action_1_sub] now reads “Used in 4–8 week blocks.” instead of the imperative “Run in blocks of 4–8 weeks.”, restoring the ER’s descriptive framing.
- 4.5 — Protocol and time-to-effect subs condensed: All six [action_#sub] and [time#_sub] entries were tightened (e.g. “Described in practitioner protocols and consistent with the rapid onset seen in animal colitis models” → “From practitioner protocols; consistent with animal colitis models”), removing about three rendered lines.
- 4.5 — Decision gates shortened: [stop_items] and [caution_items] were compressed and their example drug lists trimmed rather than dropped (e.g. “Absolute neutrophil count below 1.5 × 10⁹/L, or lymphocyte count below 1.0 × 10⁹/L at baseline” → “Baseline neutrophils below 1.5 × 10⁹/L or lymphocytes below 1.0 × 10⁹/L”); all 8 contraindications and 9 interactions are retained.
- 4.5 — Monitoring “why” cells reduced to one line each: All seven [marker_#_why] entries were cut to a single line (e.g. “Rises with inflammation independently of iron status, providing a slower-moving cross-check on hs-CRP” → “Slower-moving inflammatory cross-check on hs-CRP”), saving roughly seven rendered lines.
- 4.5 — Monitoring cadence tightened: [monitoring_cadence] was reduced from 346 to 238 characters while keeping the baseline, 8-week, off-period, 3–6 month and 4-week conditional intervals.
- 4.5 — Qualitative items trimmed: All six [qualitative_item_#] entries had their trailing explanatory clauses shortened, with the ER bold labels left verbatim.
- 4.5 — Benefit and risk tier strings compressed: The Low and Speculative benefit strings and the Low and Speculative risk strings were shortened without dropping any ER sub-heading. Total rendered body text fell from about 6,900 to 5,630 characters.